SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Al-Azayzih A, Gao F, Goc A, Somanath PR. 2012. TGFβ1 induces apoptosis in invasive prostate cancer and bladder cancer cells via Akt-independent, p38 MAPK and JNK/SAPK-mediated activation of caspases. Biochem Biophys Res Commun 427:165170.
  • Chen Y, Li L, Zeng J, Wu K, Zhou J, Guo P, Zhang D, Xue Y, Liang L, Wang X, Chang LS, He D. 2012. Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein. Chemotherapy 58:264272.
  • Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kucucuk S, Aslay I, et al. 2008. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. Cancer Invest 26:671679.
  • Gallardo A, Lerma E, Escuin D, Tibau A, Muñoz J, Ojeda B, Barnadas A, Adrover E, Sánchez-Tejada L, Giner D, Ortiz-Martínez F, Peiró G. 2012. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106:13671373.
  • Goldsmith KC, Gross M, Peirce S, Luyindula D, Liu X, Vu A, Sliozberg M, Guo R, Zhao H, Reynolds CP, Hogarty MD. 2012. Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res 72:25652577.
  • Guo X, Ma N, Wang J, Song J, Bu X, Cheng Y, Sun K, Xiong H, Jiang G, Zhang B. 2008. Increasedp38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 8:375.
  • Henríquez-Hernández LA, Navarro P, Luzardo OP, Alvarez-León EE, Boada LD, Zumbado M, Pestano J, Suárez JR, Chesa N, Almeida M, Valerón PF. 2012. Polymorphisms of glutathione S-transferase μ and θ, MDR1 and VEGF genes as risk factors of bladder cancer: a case-control study. Urol Oncol 30:660665.
  • Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stöhr R, Stöckle M, Lehmann J, Schuler M, Hartmann A. 2010. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12:628636.
  • Kunze D, Erdmann K, Froehner M, Wirth MP, Fuessel S. 2012. siRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells. Anticancer Res 32:43134318.
  • Kang YH, Ji NY, Han SR, Lee CI, Kim JW, Yeom YI, Kim YH, Chun HK, Kim JW, Chung JW, Ahn DK, Lee HG, Song EY. 2012. ESM-1 regulates cell growth and metastatic process through activation of NF-κB in colorectal cancer. Cell Signal 24:19401949.
  • Kim EJ, Lee YS, Kim YJ, Kim MJ, Ha YS, Jeong P, Lee OJ, Kim WJ. 2010. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer. Urology 75:1516.e9–13.
  • Koren R, Kugel V, Dekel Y, Weissman Y, Livne PM, Gal R. 2003. Human DNA topoisomerase-IIalpha expression as a prognostic factor for transitional cell carcinoma of the urinary bladder. BJU Int 91:489492.
  • Li J, Wang H, Ma Z, Fan W, Li Y, Han B, Zhang Z, Wang J. 2012. TAT-Apoptin induces apoptosis in the human bladder cancer EJ cell line and regulates Bax, Bcl-2, caspase-3 and survivin expression. Exp Ther Med 3:10331038.
  • Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, Pang Y, Shan Y, Xiong FX, Shao GZ, Zhou RL. 2010. LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 29:57855795.
  • Mhawech P, Herrmann F, Coassin M, Guillou L, Iselin CE. 2003. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression. Cancer 98:16491657.
  • Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M, Wu H. 2012. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72:18781889.
  • McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM. 2012. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades. Oncotarget 3:954987.
  • Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, Theodorescu D, Ostenfeld MS, Hartmann A, Borre M, Orntoft TF, Dyrskjøt L. 2012. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics 5:40.
  • Oosterlinck W, Decaestecker K. 2012. Current strategies in the treatment of non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 12:10971106.
  • Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, Gaivão I, Cardoso ML, Colaço A, Santos L, Oliveira P. 2012. Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines. J Toxicol Environ Health A 75(13-15):788799.
  • Rocco A, Compare D, Liguori E, Cianflone A, Pirozzi G, Tirino V, Bertoni A, Santoriello M, Garbi C, D'Armiento M, Staibano S, Nardone G. 2012. MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells. Lab Invest 92:14071418.
  • Roundhill EA, Burchill SA. 2012. Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria. Br J Cancer 106:12241233.
  • Suzuki M, Abe A, Imagama S, Nomura Y, Tanizaki R, Minami Y, Hayakawa F, Ito Y, Katsumi A, Yamamoto K. 2010. BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. Eur J Haematol 84:229238.
  • Tzenaki N, Andreou M, Stratigi K, Vergetaki A, Makrigiannakis A, Vanhaesebroeck B, Papakonstanti EA. 2012. High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation. FASEB J 26:24982508.
  • Wang J, Zhang J, Zhang L, Zhao L, Fan S, Yang Z, Gao F, Kong Y, Xiao GG, Wang Q. 2011. Expression of P-gp, MRP, LRP, GST-π and TopoIIα and intrinsic resistance in human lung cancer cell lines. Oncol Rep 26:10811089.
  • Weyhenmeyer B, Murphy AC, Prehn JH, Murphy BM. 2012. Targeting the anti-apoptotic bcl-2 family members for the treatment of cancer. Exp Oncol 34:192199.
  • Wu X, Zhou QH, Xu K. 2009. Are isothiocyanates potential anti-cancer drugs? Acta Pharmacol Sin 30:501512.
  • Wu X, Zhu Y, Yan H, Liu B, Li Y, Zhou Q, Xu K. 2010. Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells.BMC Cancer. 10:269279.
  • Ye QF, Zhang YC, Peng XQ, Long Z, Ming YZ, He LY. 2012. Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax. Oncol Lett 3:879884.
  • Xu JL, Wang ZW, Hu LM, Yin ZQ, Huang MD, Hu ZB, Shen HB, Shu YQ. 2012. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population. Asian Pac J Cancer Prev 13:21572162.
  • Zhang H, Sui A, Wang Z, Liu S, Yao R. 2012. Adenovirus-mediated TRAIL expression and downregulation of Bcl-2 expression suppresses non-small cell lung cancer growth in vitro and in vivo. Int J Mol Med 30:358364.